Former President Donald Trump has rolled out a comprehensive framework designed to address soaring prescription drug prices, a critical component of his broader strategy to make health care more affordable for Americans. Central to the plan is a series of regulatory proposals aimed at increasing market competition among pharmaceutical companies, including measures to streamline generic drug approvals and promote transparency in drug pricing. The initiative also includes incentives for domestic manufacturing to reduce dependency on foreign supply chains, which have contributed to price volatility.

The plan outlines multiple key actions intended to lower out-of-pocket costs and protect consumers:

  • Cap on annual out-of-pocket expenses for prescription medications
  • Enhanced negotiation powers for Medicare to secure better prices
  • Expansion of importation of safe, affordable drugs from vetted international markets
  • Promotion of value-based pricing models tied to drug efficacy
Measure Objective Expected Impact
Generic Drug Fast-Track Speed up approvals Lower prices through competition
Medicare Price Negotiations Empower negotiation Reduced drug costs for seniors
Importation Program Access to affordable drugs Expanded options for consumers
Out-of-Pocket Cap Limit patient expenses Greater financial relief